A Comprehensive Study on Patient Experiences with SYMPAZAN Oral Film
Introduction to SYMPAZAN Oral Film
The introduction of SYMPAZAN (clobazam) oral film marks a significant milestone in the treatment of patients dealing with Lennox-Gastaut Syndrome (LGS), a challenging form of childhood-onset epilepsy. This innovative formulation is the first of its kind to be recognized by the FDA for use in patients aged two years and older, offering a new therapeutic option for those grappling with the frequent and debilitating seizures associated with LGS.
Real-World Insights from the Study
Recently, Assertio Holdings, Inc. announced an exciting development: a pioneering real-world study focusing on SYMPAZAN oral film. This study was presented at a notable annual meeting, providing insights into how this medication is utilized in everyday clinical settings. The findings aim to bridge the gap between clinical efficacy and patient experience, ensuring that healthcare providers can make informed decisions tailored to patient needs.
Study Overview and Objectives
The study's primary goal was to uncover the real-world demographics of patients using SYMPAZAN, their concomitant antiseizure medication regimens, and any additional health challenges they may face. The research encompassed a population of 181 individuals diagnosed with epilepsy, including a focused subset of 29 patients specifically diagnosed with LGS.
Key Findings
Among the various conclusions drawn from the study, several noteworthy trends emerged. For instance, it was observed that patients with LGS were generally younger than those with other types of epilepsy, with an average age of 13.6 years compared to 21.1 years for the broader epilepsy group. This age discrepancy highlights the unique challenges that younger patients face in managing their condition.
Implications for Treatment
These findings shed light on the specific needs of LGS patients, particularly in the realm of medication administration. Many children have difficulties swallowing traditional tablets or liquids, making the oral film formulation of SYMPAZAN a practical solution. The data affirm the significance of considering patient preferences and capabilities when designing treatment protocols.
The Role of Healthcare Professionals
Healthcare professionals play a crucial role in incorporating this data into their practices. By understanding the real-world evidence collected from this study, clinicians can better tailor their treatment strategies, ensuring that patients receive the necessary support and therapeutic options that align with their unique situations.
Understanding Lennox-Gastaut Syndrome
Lennox-Gastaut Syndrome is recognized as a rare but severe epilepsy syndrome affecting approximately 50,000 individuals in the United States alone. Diagnosing LGS often occurs during early childhood; however, it can be misdiagnosed or overlooked until much later. Those suffering from LGS experience a range of seizures and may also encounter cognitive and behavioral difficulties. This complexity necessitates individualized treatment strategies that evolve alongside the patient's symptoms over time.
About Assertio Holdings, Inc.
Assertio is committed to addressing the diverse needs of patients through its innovative products. With a keen focus on therapeutic areas including oncology, neurology, and pain management, Assertio strives to enhance patient outcomes and quality of life. For those wishing to learn more about Assertio and its offerings, visiting their website provides ample information.
Conclusion
The recent study on SYMPAZAN oral film heralds a promising step forward in treating patients facing the challenges of Lennox-Gastaut Syndrome. By integrating patient experiences into treatment approaches, healthcare providers can foster improved outcomes and ensure that patients are better supported in their fight against epilepsy.
Frequently Asked Questions
What is SYMPAZAN oral film?
SYMPAZAN is the first FDA-approved oral film formulation of clobazam, designed to treat seizures associated with Lennox-Gastaut Syndrome in patients aged two or older.
What were the key findings of the study?
The study found that LGS patients tend to be younger and often switch from clobazam tablets or suspensions, highlighting the need for effective medication forms for those with swallowing difficulties.
How can healthcare professionals use this data?
The study offers real-world evidence that professionals can leverage to tailor treatment plans better to individual patient needs and improve therapeutic outcomes.
What is Lennox-Gastaut Syndrome?
Lennox-Gastaut Syndrome is a severe form of epilepsy characterized by multiple seizure types, cognitive challenges, and significant treatment complexities.
How does Assertio support patients?
Assertio focuses on developing innovative pharmaceutical products aimed at addressing various patient needs, particularly in oncology, neurology, and pain management.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
